Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302

BACKGROUND: Hypoxic niches in solid tumors harbor therapy-resistant cells. Hypoxia-activated prodrugs (HAPs) have been designed to overcome this resistance and, to date, have begun to show clinical efficacy. However, clinical HAPs activity could be improved. In this study, we sought to identify non-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Metab
Main Authors: Wojtkowiak, Jonathan W, Cornnell, Heather C, Matsumoto, Shingo, Saito, Keita, Takakusagi, Yoichi, Dutta, Prasanta, Kim, Munju, Zhang, Xiaomeng, Leos, Rafael, Bailey, Kate M, Martinez, Gary, Lloyd, Mark C, Weber, Craig, Mitchell, James B, Lynch, Ronald M, Baker, Amanda F, Gatenby, Robert A, Rejniak, Katarzyna A, Hart, Charles, Krishna, Murali C, Gillies, Robert J
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4310189/
https://ncbi.nlm.nih.gov/pubmed/25635223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40170-014-0026-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados